TASFYGO tasurgratinib

Drug Class

FGFR inhibitor

Mechanism

Selectively binds to and inhibits FGFR2 kinase activity, preventing downstream phosphorylation and signaling cascades in FGFR2-fusion positive tumor cells.

Approved Indication

PMDA-approved in Japan for the treatment of unresectable biliary tract cancer (BTC) harboring FGFR2 gene fusions or rearrangements that has progressed after chemotherapy.

What This Means For Patients

TASFYGO is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• PMDA — Approved (2024) — Sources

Pivotal Clinical Evidence

No peer-reviewed pivotal trial on file yet.

Sources

• https://www.pmda.go.jp/
• https://www.eisai.com/news/index.html